AVTE Stock Overview
Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Aerovate Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$21.75 |
| 52 Week High | US$32.42 |
| 52 Week Low | US$9.41 |
| Beta | 1.23 |
| 1 Month Change | -23.68% |
| 3 Month Change | 23.02% |
| 1 Year Change | 3.72% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -4.73% |
Recent News & Updates
Recent updates
Aerovate Therapeutics (NASDAQ:AVTE) Is In A Good Position To Deliver On Growth Plans
Feb 09
We're Not Very Worried About Aerovate Therapeutics' (NASDAQ:AVTE) Cash Burn Rate
Oct 17Aerovate Therapeutics (NASDAQ:AVTE) Is In A Good Position To Deliver On Growth Plans
Jul 04Aerovate Therapeutics (NASDAQ:AVTE) Is In A Good Position To Deliver On Growth Plans
Feb 28A Look At The Fair Value Of Aerovate Therapeutics, Inc. (NASDAQ:AVTE)
Jan 06Companies Like Aerovate Therapeutics (NASDAQ:AVTE) Are In A Position To Invest In Growth
Oct 14Here's Why We're Not Too Worried About Aerovate Therapeutics' (NASDAQ:AVTE) Cash Burn Situation
Jul 01We Think Aerovate Therapeutics (NASDAQ:AVTE) Can Afford To Drive Business Growth
Jan 22Companies Like Aerovate Therapeutics (NASDAQ:AVTE) Are In A Position To Invest In Growth
Sep 30Shareholder Returns
| AVTE | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -1.4% | -0.2% | 2.9% |
| 1Y | 3.7% | -1.0% | 22.2% |
Return vs Industry: AVTE exceeded the US Biotechs industry which returned 0.9% over the past year.
Return vs Market: AVTE underperformed the US Market which returned 21.9% over the past year.
Price Volatility
| AVTE volatility | |
|---|---|
| AVTE Average Weekly Movement | 12.8% |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: AVTE's share price has been volatile over the past 3 months.
Volatility Over Time: AVTE's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2018 | 51 | Tim Noyes | aerovatetx.com |
Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. The company was incorporated in 2018 and is headquartered in Waltham, Massachusetts.
Aerovate Therapeutics, Inc. Fundamentals Summary
| AVTE fundamental statistics | |
|---|---|
| Market cap | US$625.04m |
| Earnings (TTM) | -US$75.52m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-8.3x
P/E RatioIs AVTE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AVTE income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$75.52m |
| Earnings | -US$75.52m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.63 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did AVTE perform over the long term?
See historical performance and comparison